JP2019510785A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510785A5
JP2019510785A5 JP2018552218A JP2018552218A JP2019510785A5 JP 2019510785 A5 JP2019510785 A5 JP 2019510785A5 JP 2018552218 A JP2018552218 A JP 2018552218A JP 2018552218 A JP2018552218 A JP 2018552218A JP 2019510785 A5 JP2019510785 A5 JP 2019510785A5
Authority
JP
Japan
Prior art keywords
composition
combination
cell carcinoma
renal cell
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2018552218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510785A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/026819 external-priority patent/WO2017177230A1/en
Publication of JP2019510785A publication Critical patent/JP2019510785A/ja
Publication of JP2019510785A5 publication Critical patent/JP2019510785A5/ja
Priority to JP2022010811A priority Critical patent/JP2022044767A/ja
Ceased legal-status Critical Current

Links

JP2018552218A 2016-04-08 2017-04-10 癌を処置する方法 Ceased JP2019510785A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022010811A JP2022044767A (ja) 2016-04-08 2022-01-27 癌を処置する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662319857P 2016-04-08 2016-04-08
US62/319,857 2016-04-08
PCT/US2017/026819 WO2017177230A1 (en) 2016-04-08 2017-04-10 Methods for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022010811A Division JP2022044767A (ja) 2016-04-08 2022-01-27 癌を処置する方法

Publications (2)

Publication Number Publication Date
JP2019510785A JP2019510785A (ja) 2019-04-18
JP2019510785A5 true JP2019510785A5 (https=) 2021-01-07

Family

ID=60001518

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018552218A Ceased JP2019510785A (ja) 2016-04-08 2017-04-10 癌を処置する方法
JP2022010811A Pending JP2022044767A (ja) 2016-04-08 2022-01-27 癌を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022010811A Pending JP2022044767A (ja) 2016-04-08 2022-01-27 癌を処置する方法

Country Status (6)

Country Link
US (1) US11337969B2 (https=)
EP (1) EP3440112A4 (https=)
JP (2) JP2019510785A (https=)
CN (1) CN109153722A (https=)
CA (1) CA3019394A1 (https=)
WO (1) WO2017177230A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
PL3393468T3 (pl) 2015-12-22 2023-01-23 X4 Pharmaceuticals, Inc. Metody leczenia niedoboru odporności
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
US20210349099A1 (en) * 2017-11-07 2021-11-11 X4 Pharmaceuticals, Inc. Cancer biomarkers and methods of use thereof
JP2021521439A (ja) * 2018-04-13 2021-08-26 エックス４ ファーマシューティカルズ， インコーポレイテッド がん血清バイオマーカーおよびその使用方法
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
CN116246795B (zh) * 2023-05-12 2023-07-21 中国医学科学院北京协和医院 一种检测样本中外周血生物标志物的试剂在制备预测食管癌化疗疗效的产品中的应用

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4933447A (en) 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9200245D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
US5235056A (en) 1992-04-22 1993-08-10 Ciba-Geigy Corporation Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
WO1997009976A2 (en) 1995-09-01 1997-03-20 Washington University Method of reducing neurotoxic injury with zinc chelators
PL329070A1 (en) 1996-03-22 1999-03-15 Du Pont Pharm Co Novel dissymetrical synthesis of r-alpha-propylpiperonylamine and its analoques
CN100525766C (zh) 1997-06-02 2009-08-12 詹森药业有限公司 用作平滑肌细胞增殖抑制剂的（咪唑-5-基）甲基-2-喹啉酮衍生物
WO1999004794A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
EP1031563B1 (en) 1997-09-30 2005-12-28 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
GB9726229D0 (en) 1997-12-12 1998-02-11 Zeneca Ltd Resolution of chiral amines
US6172061B1 (en) 1997-12-19 2001-01-09 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
US6607799B1 (en) 1998-10-15 2003-08-19 3M Innovative Properties Company Surgical dressing with delivery system and method of manufacture
US6635278B1 (en) 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
BR0010655A (pt) 1999-03-24 2002-02-13 Anormed Inc Compostos heterocìclicos para ligação ao receptor de quimiocina
US6245799B1 (en) 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6835731B2 (en) 2000-09-15 2004-12-28 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
PT1317451E (pt) 2000-09-15 2006-12-29 Anormed Inc Compostos heterocíclicos que se ligam a receptores de quimioquinas
CA2419224A1 (en) 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
MXPA03005152A (es) 2000-12-11 2004-10-14 Tularik Inc Antogonista de cxcr3.
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
EP1389617B1 (en) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
ES2380009T3 (es) 2001-07-31 2012-05-07 Genzyme Global S.A.R.L. Métodos para movilizar las células madre/progenitoras
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
WO2003022785A2 (en) 2001-09-12 2003-03-20 Anormed Inc. Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CA2467718C (en) 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7491544B2 (en) 2002-05-20 2009-02-17 New York University Chiral piperidine and quinucledine ligands
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
WO2004052862A1 (ja) 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
KR20070087266A (ko) 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. 피아이-3 키나아제 억제제 프로드러그
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
US7501518B2 (en) 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
AU2004232361A1 (en) 2003-04-22 2004-11-04 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CN1832939B (zh) 2003-05-30 2010-04-28 杰明X医药品加拿大公司 用于治疗癌症或病毒病的三杂环化合物、组合物和方法
US7173015B2 (en) 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
CN1930127B (zh) 2004-03-15 2012-11-21 阿诺麦德股份有限公司 用于合成cxcr4拮抗剂的方法
EP1742936A2 (en) 2004-04-13 2007-01-17 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
DE102004021716A1 (de) 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
US20080096861A1 (en) 2004-08-02 2008-04-24 Smithkline Beecham Corporation Chemical Compounds
CA2577100A1 (en) 2004-08-16 2006-03-02 Smithkline Beecham Corporation Chemical compounds
JP2008511669A (ja) 2004-09-02 2008-04-17 スミスクライン ビーチャム コーポレーション 化合物
WO2006036816A2 (en) 2004-09-24 2006-04-06 Smithkline Beecham Corporation Chemical compounds
TW200619206A (en) 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US20090093454A1 (en) 2005-03-04 2009-04-09 Kristjan Gudmundsson Chemical Compounds
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20090203533A1 (en) 2005-07-08 2009-08-13 Siemens Medicals Solutions Diagnositcs Gmbh Methods and Kits for Predicting and Monitoring Direct Response to Cancer Therapy
US20080214562A1 (en) 2005-07-11 2008-09-04 Kristjan Gudmundsson Chemical Compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
WO2007015074A1 (en) 2005-08-02 2007-02-08 Ineos Europe Limited Diene polymerisation
CA2619828A1 (en) 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
EP1919872A4 (en) 2005-08-31 2009-08-05 Smithkline Beecham Corp CHEMICAL COMPOUNDS
BRPI0617162B8 (pt) 2005-10-07 2021-05-25 Exelixis Inc compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
US20070123538A1 (en) 2005-11-30 2007-05-31 Schering Corporation Compositions comprising a combination of CCR5 and CXCR4 antagonists
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
JP2009524689A (ja) 2006-01-25 2009-07-02 スミスクライン ビーチャム コーポレーション 化合物
PE20070946A1 (es) 2006-01-25 2007-10-16 Smithkline Beecham Corp COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4)
GB0605786D0 (en) 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
CN101466376A (zh) 2006-06-12 2009-06-24 辉瑞产品公司 用于提高免疫重建并治疗hiv患者的机会感染的ccr5拮抗剂
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
CN101855222A (zh) 2007-05-10 2010-10-06 通用电气健康护理有限公司 对大麻素cb2受体具有活性的咪唑并(1,2-a)吡啶和相关化合物
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US20110070657A1 (en) 2007-08-17 2011-03-24 The General Hospital Corporation Detecting ions and measuring ion concentrations
US9101628B2 (en) 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
CN102088993A (zh) 2008-03-20 2011-06-08 卡罗勒斯治疗公司 炎症的治疗方法
AU2009228034A1 (en) 2008-03-28 2009-10-01 Altiris Therapeutics Chemokine receptor modulators
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP2010016628A (ja) 2008-07-03 2010-01-21 Canon Inc 画像処理装置及び画像処理方法
MX2011001782A (es) 2008-08-13 2012-02-08 Vertex Pharma Composicion farmaceutica y su administracion.
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
EP2213288A1 (en) 2009-01-30 2010-08-04 Karl Welte NAMPT and vitamin B3 for treating or preventing diseases
EP2482805B1 (en) 2009-09-28 2014-11-19 Zenbury International Limited Pharmaceutical composition
CA2706292A1 (en) 2010-05-28 2011-11-28 Pharmascience Inc. A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
US20110293686A1 (en) 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
US9155723B2 (en) 2010-06-28 2015-10-13 The General Hospital Corporation Anti-CXCR4 as a sensitizer to cancer therapeutics
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
US9267934B2 (en) 2010-10-26 2016-02-23 University Of South Alabama Methods and compositions for ameliorating pancreatic cancer
EP3153510B1 (en) 2010-12-03 2020-05-06 Emory University Fused azines as chemokine cxcr4 receptor modulators and uses related thereto
JP6076913B2 (ja) 2010-12-07 2017-02-08 ドレクセル ユニバーシティ 癌からの転移を阻害する方法
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN103476410B (zh) 2011-01-11 2020-02-21 戴麦里克斯生物科学有限公司 联合疗法
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
AR087364A1 (es) 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
AR087363A1 (es) 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
JP2015503624A (ja) 2012-01-12 2015-02-02 ギリアード サイエンシーズ， インコーポレイテッド 医薬組成物およびその調製方法
EP2922861A4 (en) 2012-11-26 2016-09-14 Caris Life Sciences Switzerland Holdings Gmbh BIOMARKER COMPOSITIONS AND METHODS
US10064826B2 (en) 2013-03-15 2018-09-04 Navinta, Llc Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
WO2014197680A1 (en) * 2013-06-05 2014-12-11 Salk Institute For Biological Studies Vitamin d receptor agonists to treat diseases involving cxcl12 activity
AT512724B1 (de) 2013-07-12 2015-02-15 Avl List Gmbh Vorrichtung und Verfahren zur kontinuierlichen Messung des dynamischen Kraftstoffverbrauchs einer Brennkraftmaschine
PE20160671A1 (es) 2013-08-02 2016-07-09 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco
CA2920377A1 (en) 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
CA3206628A1 (en) 2013-09-12 2015-03-19 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating waldenstrom's macroglobulinemia
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
EP3114144A1 (en) * 2014-03-05 2017-01-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
WO2015143092A1 (en) 2014-03-18 2015-09-24 The Research Foundation For The State University Of New York Therapeutic agent for treating tumors
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
EP3157921A1 (en) 2014-06-23 2017-04-26 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
DK3169341T3 (da) 2014-07-16 2019-08-05 Transgene Sa Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
ES2754549T3 (es) 2014-12-03 2020-04-20 Glycomimetics Inc Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4
EP3230498B1 (en) 2014-12-09 2023-01-18 Merck Sharp & Dohme LLC System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
SG11201704756YA (en) 2014-12-12 2017-07-28 Commw Scient Ind Res Org Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
EP3307778A1 (en) 2015-06-12 2018-04-18 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10379661B2 (en) 2015-09-25 2019-08-13 Samsung Electronics Co., Ltd. Coordinate measuring apparatus and coordinate measuring system having the same
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
PL3393468T3 (pl) 2015-12-22 2023-01-23 X4 Pharmaceuticals, Inc. Metody leczenia niedoboru odporności
CA3010617A1 (en) 2016-01-22 2017-07-27 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES3014978T3 (en) 2016-04-14 2025-04-28 Creatv Microtech Inc Methods of using pd-l1 expression in treatment decisions for cancer therapy
CA3019182A1 (en) 2016-04-29 2017-11-02 Dana-Farber Cancer Institute, Inc. Hck as a therapeutic target in myd88 mutated diseases
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
JP2020525427A (ja) 2017-06-21 2020-08-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置するための方法
US20210349099A1 (en) 2017-11-07 2021-11-11 X4 Pharmaceuticals, Inc. Cancer biomarkers and methods of use thereof
WO2019126106A1 (en) 2017-12-19 2019-06-27 X4 Pharmaceuticals, Inc. Acyclic cxcr4 inhibitors and uses thereof
JP2021521439A (ja) 2018-04-13 2021-08-26 エックス４ ファーマシューティカルズ， インコーポレイテッド がん血清バイオマーカーおよびその使用方法
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2021127496A1 (en) 2019-12-18 2021-06-24 X4 Pharmaceuticals, Inc. Combination treatments for waldenstrom's macroglobulinemia
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia

Similar Documents

Publication Publication Date Title
JP2019510785A5 (https=)
Hack et al. Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities
Xu et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study
JP2019502741A5 (https=)
Olszanski Current and future roles of targeted therapy and immunotherapy in advanced melanoma
Tabchi et al. Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab
Löhr et al. A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer
Watanabe et al. Congestive heart failure during osimertinib treatment for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)
Cho et al. Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer
Wei et al. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
JP2012522837A5 (https=)
JPWO2020111018A5 (https=)
Liu et al. Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial
TW201141473A (en) Combination therapy for small cell lung cancer
Starr Encouraging results for pembrolizumab in head and neck cancer
Ning et al. Anti‐PD‐L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy‐refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study
Kim et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer
Karampeazis et al. Docetaxel vs. vinorelbine in elderly patients with advanced non–small-cell lung cancer: a hellenic oncology research group randomized phase III study
Chen et al. Clinical value of propranolol combined with oxaliplatin and tigio in concurrent chemoradiotherapy for locally advanced gastric cancer
Tian et al. Secondary pneumothorax as a potential marker of apatinib efficacy in osteosarcoma: a multicenter analysis
Xu Clinical study of nimotuzumab combined with chemotherapy in the treatment of late stage gastric cancer
Kong et al. The FJQR has synergistic effect with fluoropyrimidine in the maintenance treatment for HER-2 negative gastric cancer
Liu et al. Water‐filtered infrared A radiation hyperthermia combined with immunotherapy for advanced gastrointestinal tumours
CN110507651B (zh) 一种具有抗非小细胞肺癌作用的药物及其用途
Cheng et al. Clinical efficacy of pseudomonas aeruginosa injection combined with endostar in the treatment of malignant pleural effusion: a randomized trial